Who are we?
Biopharmaceutical company engaged in the development of novel therapeutics for the treatment of cancer. Utilizing an immunotherapeutic approach, the company is exploring the development of novel, fully human antibody-based blockade therapeutics in an effort to generate new immuno-oncology treatments.